

## Mediclose™




### Year to date Milestones 2020

<b>Funding</b>	Pre-seed 600 K (2015) Series A (2018/2020) at € 5 M
<b>Patents</b>	2 patent families
<b>Trade Marks</b>	MEDICLOSE™
<b>QA - QMS</b>	ISO13485 certified
<b>Regulatory</b>	MEDICLOSE™ class 3
<b>Focus 2020</b>	Clinical assessment
<b>First in man</b>	Supply to hospitals
<b>MEDICLOSE™</b>	Large scale manufacturing and Supply Chain in place
<b>M&amp;S activities</b>	First sales

### Key Value Drivers 2020-2025

<b>MEDICLOSE™</b>	First in Man (FIM): 2021 CE & start Sales: 2021
<b>US FIM &amp; Product launch</b>	MEDICLOSE™: 2022 Follow 510K predicate
<b>Co- US-FDA registration</b>	
<b>Distribution</b>	EU and ROW; US through co-development partner.
<b>Product pipeline</b>	LAPRIXA™ new applications
<b>Location HQ R&amp;D and Buss dev.</b>	MHC campus, Maastricht, Netherlands



**Corporis Medical** +31 43 388 2948  
**Oxfordlaan 55** John.marugg@corporis-medical.com  
**6229 EV Maastricht**

### The Company

Corporis Medical is a young medical device company which started its operations in 2015, focusing on developing innovative solutions for improving access, closure, and diagnostic measurements for minimally invasive interventional procedures. The company has several products in development in collaboration with key opinion leaders, designers, suppliers, and distributors. Our primary product, MEDICLOSE™, is designed to automatically close trocar induced wounds at the end of laparoscopic surgery.

### Mediclose™

Mediclose™ is our **sterile, disposable, and automated suturing device**. Its **unique design** that fits any commercial trocar allows for extremely fast closure (wounds can be closed within a minute). Furthermore, its one-hand activation and no additional tools or camera control required make this device easy to use. As such, Mediclose™ reduces time necessary to close trocar induced wounds and significantly lowers the risk of a post-surgery herniation. Lastly, most existing suture systems close trocar induced incisions from outside inward, while the Mediclose™ system was designed to close incision from inside outward, with the position of the needles pointing away from any vital organs. Therefore, Mediclose™ presents **safer and faster** way of trocar wound closure saving not only valuable or time but also limited health care resources.

### The market opportunities

Laparoscopic surgery is quickly gaining ground in all fields of surgery due to its enhanced recovery. It is estimated that there are upwards to 20 million laparoscopic procedures performed worldwide every year. For EU and US combined, this sums up to ~10 million laparoscopic surgeries are performed annually. Currently, Mediclose™ is starting its human clinical trials. CE-mark approval and sales are expected in 2021.

### Distribution and co-sell partnership

With a total market of 10 million laparoscopic procedures yearly Corporis Medical could save and improve thousands of lives with their new laparoscopic interventions. In order to be able to distribute and sell Mediclose™ in the large market, **Corporis Medical is looking for distribution partners specialized in surgical tools and selling directly to hospitals, partners to co-sell and/or incorporate Mediclose™ as part of their laparoscopic surgical tools' portfolios or trocar kits.**

### Contact Details